BC Week In Review | Aug 30, 2010
Company News

Raptor, Uni Pharma Co. Ltd. deal

Raptor granted Uni Pharma an exclusive license to commercialize Convivia in Taiwan, with an option for rights in Korea. Uni Pharma will be responsible for clinical development and registration in the country. The oral 4-methylpyrazole...
BC Week In Review | Nov 17, 2008
Clinical News

Convivia: Phase IIa data

In a double-blind, dose-escalation, U.S. Phase IIa trial in 32 patients of Japanese descent with ALDH2 deficiency, oral Convivia significantly reduced heart palpitations following alcohol consumption. Convivia also significantly reduced peak acetaldehyde levels and total...
BC Week In Review | Apr 28, 2008
Clinical News

Convivia: Phase IIa started

Raptor's Bennu Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial of oral Convivia in up to 32 patients of Japanese descent. Raptor Pharmaceutical Corp. (OTCBB:RPTP), Novato, Calif.   Product: Convivia  ...
BC Week In Review | Oct 29, 2007
Company News

Convivia Inc., Raptor deal

RPTP acquired a clinical program targeting aldehyde dehydrogenase ( ALDH2 ) deficiency from Convivia for 200,000 RPTP shares worth $110,000 based on RPTP's close of $0.55 on Oct. 19, the last trading day before the deal was...
Items per page:
1 - 4 of 4